<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05047718</url>
  </required_header>
  <id_info>
    <org_study_id>21CH134</org_study_id>
    <secondary_id>2021-003547-24</secondary_id>
    <nct_id>NCT05047718</nct_id>
  </id_info>
  <brief_title>Factors Influencing the COVID-19 Vaccine Immune Response According to Age and Presence or Not of a Past History of COVID-19</brief_title>
  <acronym>COVIMMUNAGE</acronym>
  <official_title>Factors Influencing the COVID-19 Vaccine Immune Response (Reactogenicity and Immunogenicity) According to Age and Presence or Not of a Past History of COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi Pasteur, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bioaster</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Saint Etienne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Age is the main risk factor associated with the severity of COVID-19. From the beginning of&#xD;
      the vaccination campaign, elderly subjects are part of the priority population. However,&#xD;
      immunosenescence appears to play a role in the natural post-COVID-19 immunity of convalescent&#xD;
      elderly subjects and also in the post-vaccination response. However, vaccination&#xD;
      recommendations for both naïve (2 doses of vaccine) and convalescent subjects (1 dose of&#xD;
      vaccine) do not differ according to age. To date, there is little data to suggest that the&#xD;
      response to the vaccine in naïve or convalescent subjects may vary according to age in terms&#xD;
      of qualitative and quantitative response and duration.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In addition, the reactogenicity following the vaccine, remains important with COVID-19&#xD;
      vaccines, whether using an Messenger RiboNucleic Acid (mRNA) technique or an adenovirus&#xD;
      vector technique. A better understanding of the parameters of early inflammatory response&#xD;
      explaining this reactogenicity would allow to optimize the formulation of future vaccines.&#xD;
      There are still several unknowns concerning the post-vaccination immune response&#xD;
      (immunogenicity and reactogenicity) in older subjects,depending on their history of COVID-19&#xD;
      and the type of vaccine administered. A better understanding of this immune response is&#xD;
      necessary in order to propose the best vaccine strategies and regimens in this high-risk&#xD;
      COVID-19 population.&#xD;
&#xD;
      Thus, in partnership with Sanofi Pasteur and Bioaster, the Group On Mucosal Immunity And&#xD;
      Pathogens (GIMAP) and Circulating Immune Complexes (CIC) vaccinology team proposes to conduct&#xD;
      a study comparing the humoral, cellular, mucosal and reactogenic post-vaccination immune&#xD;
      response in subjects with a history of COVID-19 &gt;3 months ago (convalescent, 1 dose of&#xD;
      vaccine) versus subjects with no history of COVID-19 (naive, 1 or 2 doses of vaccine&#xD;
      depending on the type of vaccine used) according to age.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 5, 2021</start_date>
  <completion_date type="Anticipated">March 3, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Anti-S neutralizing antibody titer</measure>
    <time_frame>At 15 days after the last dose of vaccine</time_frame>
    <description>The neutralizing antibody titer against protein S from the majority variants at the time of sampling and vaccine S will be evaluated in viral neutralization and pseudoneutralization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Kinetic of Anti-S antibody titer</measure>
    <time_frame>At 15 days, 3, 6 and 12 months after the last dose of vaccine</time_frame>
    <description>The antibody titer against protein S will be evaluated by ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kinetic of Anti-N antibody titer</measure>
    <time_frame>At 15 days, 3, 6 and 12 months after the last dose of vaccine</time_frame>
    <description>The antibody titer against protein N will be evaluated by ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kinetic of Anti-SARS-CoV-2 immunoglobulin A (IgA) titers in saliva</measure>
    <time_frame>At 15 days, 3, 6 and 12 months after the last dose of vaccine</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kinetic of SARS-CoV-2 quantiferon value</measure>
    <time_frame>At 15 days, 3, 6 and 12 months after the last dose of vaccine</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD4 and CD8 lymphocyte polarization specific to the vaccine S protein</measure>
    <time_frame>At 15 days after the last dose of vaccine</time_frame>
    <description>Evaluate by TruCulture (Myriad) methode</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-S neutralizing antibody titer</measure>
    <time_frame>At 3, 6 and 12 months after the last dose of vaccine</time_frame>
    <description>The neutralizing antibody titer against protein S from the majority variants at the time of sampling and vaccine S will be evaluated in viral neutralization and pseudoneutralization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kinetic of serum cytokine levels</measure>
    <time_frame>At 24 and 72 hours after each dose of vaccine</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kinetic of C-reactive protein</measure>
    <time_frame>At 24 and 72 hours after each dose of vaccine</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kinetic of vaccine-induced genes signatures</measure>
    <time_frame>At 24 and 72 hours after each dose of vaccine</time_frame>
    <description>Expression kinetics in foldchange (transcriptomics) of vaccine-induced gene signatures in peripheral blood mononuclear cells</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>convalescent participants PFIZER</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with prior history of COVID-19 in ≥3 months, virologically confirmed and vaccinated by anti-covid19 Pfizer vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Naive participants PFIZER</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participant without past history of COVID-19 and vaccinated by anti-covid19 Pfizer vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>convalescent participants MODERNA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with prior history of COVID-19 in ≥3 months, virologically confirmed and vaccinated by anti-covid19 Moderna vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Naive participants MODERNA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participant without past history of COVID-19 and vaccinated by anti-covid19 Moderna vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>COVID-19 vaccine Pfizer (2 doses)</intervention_name>
    <description>A longitudinal analysis of the immune response post COVID-19 vaccine will be performed with a close immunomonitoring</description>
    <arm_group_label>Naive participants PFIZER</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>COVID-19 vaccine Pfizer (1 dose)</intervention_name>
    <description>A longitudinal analysis of the immune response post COVID-19 vaccine will be performed with a close immunomonitoring</description>
    <arm_group_label>convalescent participants PFIZER</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>COVID-19 mRNA Vaccine Moderna (2 doses)</intervention_name>
    <description>A longitudinal analysis of the immune response post COVID-19 vaccine will be performed with a close immunomonitoring</description>
    <arm_group_label>Naive participants MODERNA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>COVID-19 mRNA Vaccine Moderna (1 dose)</intervention_name>
    <description>A longitudinal analysis of the immune response post COVID-19 vaccine will be performed with a close immunomonitoring</description>
    <arm_group_label>convalescent participants MODERNA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  For the group with a past history of COVID-19 (convalescents)= subject within ≥ 3&#xD;
             months after infection&#xD;
&#xD;
          -  For the NO past history of COVID-19 (naives), subject with no known history of&#xD;
             COVID-19&#xD;
&#xD;
          -  Patient affiliated or entitled to a social security plan&#xD;
&#xD;
          -  Patients who have received informed information about the study and who have co-signed&#xD;
             a consent to participate in the study with the investigator&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Immunocompromised or under immunosuppressive treatment&#xD;
&#xD;
          -  Subject with a history of COVID hospitalized in intensive care&#xD;
&#xD;
          -  Subject allergic to one of the components of the vaccines used in the study&#xD;
&#xD;
          -  subject vaccinated for COVID-19&#xD;
&#xD;
          -  Subject with persistent symptoms of COVID-19 (long COVID)&#xD;
&#xD;
          -  Subjects with unstable chronic pathology&#xD;
&#xD;
          -  Persons deprived of liberty, hospitalized without consent&#xD;
&#xD;
          -  Pregnant or breastfeeding woman&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elisabeth BOTELHO-NEVERS, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de St Etienne</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elisabeth BOTELHO-NEVERS, MD PhD</last_name>
    <phone>(0)477120790</phone>
    <phone_ext>+33</phone_ext>
    <email>elisabeth.botelho-nevers@chu-st-etienne.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maelle DETOC, PhD</last_name>
    <phone>(0)477829675</phone>
    <phone_ext>+33</phone_ext>
    <email>maelle.detoc@chu-st-etienne.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>HCL - Hôpital Croix Rousse</name>
      <address>
        <city>Lyon</city>
        <zip>69004</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Anne CONRAD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HCL - Hôpital Edouard Herriot</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Philippe VANHEMS, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Saint-Etienne</name>
      <address>
        <city>Saint-Étienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Elisabeth BOTELHO-NEVERS, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas CELARIER, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carole PELISSIER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 14, 2021</study_first_submitted>
  <study_first_submitted_qc>September 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2021</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immunogenicity</keyword>
  <keyword>reactogenicity</keyword>
  <keyword>mRNA COVID-19 vaccine</keyword>
  <keyword>COVID-19 natural immunity</keyword>
  <keyword>age</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

